Two of the nation's biggest nonprofit health systems—Dignity Health and Catholic Health Initiatives—launched a precision medicine program that has the potential to create the largest collection of clinical cancer data ever compiled by a single organization.
After raising $1 billion for Knight Cancer Institute, the Oregon Health and Science University fundraising team set out to raise another $1 billion over five years—before 2020.
The National Cancer Moonshot Initiative is not slated to receive funding in fiscal 2017—neither the House nor Senate appropriations bill includes the $680 million the White House proposed for Vice President Joe Biden's project.
Dan Sargent, one of the world's foremost experts in oncology clinical trials, died unexpectedly on Sept. 22. Sargent died from an acute illness, Mayo officials said. He was 46.
FDA has recommended against the use of ovarian cancer screening tests, regardless of risk level.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies for August. For further information, contact the principal investigator listed.
FDA granted Breakthrough Therapy designation to LEE011 (ribociclib), in combination with letrozole, for the treatment of hormone receptor positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer. LEE011 is a selective cyclin dependent kinase (CDK4/6) inhibitor.
A new class of drugs called HIF-2 inhibitors is more effective and better tolerated than the standard of care drug sunitinib in treating kidney cancer, researchers with the Kidney Cancer Program at Harold C. Simmons Comprehensive Cancer Center have found.
Celsion Corp. said NIH has conducted an independent retrospective analysis of data from the intent-to-treat population of the Company's HEAT Study, a 701-patient study investigating ThermoDox, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin in combination with radiofrequency ablation in primary hepatocellular carcinoma.
Combining two immunotherapy drugs upfront for advanced melanoma appears to increase the two-year survival rate over that achieved with a single agent, according to an analysis of results from a multi-center phase II clinical trial, scientists report.
